

# **Bile Duct Cancer Drug-Global Market Status and Trend Report 2013-2023**

<https://marketpublishers.com/r/B553F4D9968MEN.html>

Date: May 2018

Pages: 130

Price: US\$ 2,480.00 (Single User License)

ID: B553F4D9968MEN

## **Abstracts**

### **Report Summary**

Bile Duct Cancer Drug-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bile Duct Cancer Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Bile Duct Cancer Drug 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Bile Duct Cancer Drug worldwide, with company and product introduction, position in the Bile Duct Cancer Drug market

Market status and development trend of Bile Duct Cancer Drug by types and applications

Cost and profit status of Bile Duct Cancer Drug, and marketing status

Market growth drivers and challenges

The report segments the global Bile Duct Cancer Drug market as:

Global Bile Duct Cancer Drug Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Bile Duct Cancer Drug Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Cabozantinib S-malate

Elpamotide

Exatecan Mesylate

LY-2801653

NUC-1031

Others

Global Bile Duct Cancer Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Others

Global Bile Duct Cancer Drug Market: Manufacturers Segment Analysis (Company and Product introduction, Bile Duct Cancer Drug Sales Volume, Revenue, Price and Gross Margin):

Ariad Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

Aslan Pharmaceuticals Pte. Ltd.

Bavarian Nordic A/S

Bayer AG

Blueprint Medicines Corporation

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

CellAct Pharma GmbH

Cellceutix Corporation

Cellular Biomedicine Group, Inc.

Concordia Healthcare Corp.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF BILE DUCT CANCER DRUG**

- 1.1 Definition of Bile Duct Cancer Drug in This Report
- 1.2 Commercial Types of Bile Duct Cancer Drug
  - 1.2.1 Cabozantinib S-malate
  - 1.2.2 Elpamotide
  - 1.2.3 Exatecan Mesylate
  - 1.2.4 LY-2801653
  - 1.2.5 NUC-1031
  - 1.2.6 Others
- 1.3 Downstream Application of Bile Duct Cancer Drug
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Others
- 1.4 Development History of Bile Duct Cancer Drug
- 1.5 Market Status and Trend of Bile Duct Cancer Drug 2013-2023
  - 1.5.1 Global Bile Duct Cancer Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Bile Duct Cancer Drug Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Bile Duct Cancer Drug 2013-2017
- 2.2 Sales Market of Bile Duct Cancer Drug by Regions
  - 2.2.1 Sales Volume of Bile Duct Cancer Drug by Regions
  - 2.2.2 Sales Value of Bile Duct Cancer Drug by Regions
- 2.3 Production Market of Bile Duct Cancer Drug by Regions
- 2.4 Global Market Forecast of Bile Duct Cancer Drug 2018-2023
  - 2.4.1 Global Market Forecast of Bile Duct Cancer Drug 2018-2023
  - 2.4.2 Market Forecast of Bile Duct Cancer Drug by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Bile Duct Cancer Drug by Types
- 3.2 Sales Value of Bile Duct Cancer Drug by Types
- 3.3 Market Forecast of Bile Duct Cancer Drug by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM**

## **INDUSTRY**

- 4.1 Global Sales Volume of Bile Duct Cancer Drug by Downstream Industry
- 4.2 Global Market Forecast of Bile Duct Cancer Drug by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Bile Duct Cancer Drug Market Status by Countries
  - 5.1.1 North America Bile Duct Cancer Drug Sales by Countries (2013-2017)
  - 5.1.2 North America Bile Duct Cancer Drug Revenue by Countries (2013-2017)
  - 5.1.3 United States Bile Duct Cancer Drug Market Status (2013-2017)
  - 5.1.4 Canada Bile Duct Cancer Drug Market Status (2013-2017)
  - 5.1.5 Mexico Bile Duct Cancer Drug Market Status (2013-2017)
- 5.2 North America Bile Duct Cancer Drug Market Status by Manufacturers
- 5.3 North America Bile Duct Cancer Drug Market Status by Type (2013-2017)
  - 5.3.1 North America Bile Duct Cancer Drug Sales by Type (2013-2017)
  - 5.3.2 North America Bile Duct Cancer Drug Revenue by Type (2013-2017)
- 5.4 North America Bile Duct Cancer Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Bile Duct Cancer Drug Market Status by Countries
  - 6.1.1 Europe Bile Duct Cancer Drug Sales by Countries (2013-2017)
  - 6.1.2 Europe Bile Duct Cancer Drug Revenue by Countries (2013-2017)
  - 6.1.3 Germany Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.4 UK Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.5 France Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.6 Italy Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.7 Russia Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.8 Spain Bile Duct Cancer Drug Market Status (2013-2017)
  - 6.1.9 Benelux Bile Duct Cancer Drug Market Status (2013-2017)
- 6.2 Europe Bile Duct Cancer Drug Market Status by Manufacturers
- 6.3 Europe Bile Duct Cancer Drug Market Status by Type (2013-2017)
  - 6.3.1 Europe Bile Duct Cancer Drug Sales by Type (2013-2017)
  - 6.3.2 Europe Bile Duct Cancer Drug Revenue by Type (2013-2017)
- 6.4 Europe Bile Duct Cancer Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Bile Duct Cancer Drug Market Status by Countries
  - 7.1.1 Asia Pacific Bile Duct Cancer Drug Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Bile Duct Cancer Drug Revenue by Countries (2013-2017)
  - 7.1.3 China Bile Duct Cancer Drug Market Status (2013-2017)
  - 7.1.4 Japan Bile Duct Cancer Drug Market Status (2013-2017)
  - 7.1.5 India Bile Duct Cancer Drug Market Status (2013-2017)
  - 7.1.6 Southeast Asia Bile Duct Cancer Drug Market Status (2013-2017)
  - 7.1.7 Australia Bile Duct Cancer Drug Market Status (2013-2017)
- 7.2 Asia Pacific Bile Duct Cancer Drug Market Status by Manufacturers
- 7.3 Asia Pacific Bile Duct Cancer Drug Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Bile Duct Cancer Drug Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Bile Duct Cancer Drug Revenue by Type (2013-2017)
- 7.4 Asia Pacific Bile Duct Cancer Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 8.1 Latin America Bile Duct Cancer Drug Market Status by Countries
  - 8.1.1 Latin America Bile Duct Cancer Drug Sales by Countries (2013-2017)
  - 8.1.2 Latin America Bile Duct Cancer Drug Revenue by Countries (2013-2017)
  - 8.1.3 Brazil Bile Duct Cancer Drug Market Status (2013-2017)
  - 8.1.4 Argentina Bile Duct Cancer Drug Market Status (2013-2017)
  - 8.1.5 Colombia Bile Duct Cancer Drug Market Status (2013-2017)
- 8.2 Latin America Bile Duct Cancer Drug Market Status by Manufacturers
- 8.3 Latin America Bile Duct Cancer Drug Market Status by Type (2013-2017)
  - 8.3.1 Latin America Bile Duct Cancer Drug Sales by Type (2013-2017)
  - 8.3.2 Latin America Bile Duct Cancer Drug Revenue by Type (2013-2017)
- 8.4 Latin America Bile Duct Cancer Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 9.1 Middle East and Africa Bile Duct Cancer Drug Market Status by Countries

- 9.1.1 Middle East and Africa Bile Duct Cancer Drug Sales by Countries (2013-2017)
- 9.1.2 Middle East and Africa Bile Duct Cancer Drug Revenue by Countries (2013-2017)
- 9.1.3 Middle East Bile Duct Cancer Drug Market Status (2013-2017)
- 9.1.4 Africa Bile Duct Cancer Drug Market Status (2013-2017)
- 9.2 Middle East and Africa Bile Duct Cancer Drug Market Status by Manufacturers
- 9.3 Middle East and Africa Bile Duct Cancer Drug Market Status by Type (2013-2017)
  - 9.3.1 Middle East and Africa Bile Duct Cancer Drug Sales by Type (2013-2017)
  - 9.3.2 Middle East and Africa Bile Duct Cancer Drug Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Bile Duct Cancer Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BILE DUCT CANCER DRUG**

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Bile Duct Cancer Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 11 BILE DUCT CANCER DRUG MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

- 11.1 Production Volume of Bile Duct Cancer Drug by Major Manufacturers
- 11.2 Production Value of Bile Duct Cancer Drug by Major Manufacturers
- 11.3 Basic Information of Bile Duct Cancer Drug by Major Manufacturers
  - 11.3.1 Headquarters Location and Established Time of Bile Duct Cancer Drug Major Manufacturer
  - 11.3.2 Employees and Revenue Level of Bile Duct Cancer Drug Major Manufacturer
- 11.4 Market Competition News and Trend
  - 11.4.1 Merger, Consolidation or Acquisition News
  - 11.4.2 Investment or Disinvestment News
  - 11.4.3 New Product Development and Launch

## **CHAPTER 12 BILE DUCT CANCER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 12.1 Ariad Pharmaceuticals, Inc.
  - 12.1.1 Company profile
  - 12.1.2 Representative Bile Duct Cancer Drug Product
  - 12.1.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Ariad

Pharmaceuticals, Inc.

12.2 ArQule, Inc.

12.2.1 Company profile

12.2.2 Representative Bile Duct Cancer Drug Product

12.2.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of ArQule, Inc.

12.3 Array BioPharma Inc.

12.3.1 Company profile

12.3.2 Representative Bile Duct Cancer Drug Product

12.3.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Array

BioPharma Inc.

12.4 Arrien Pharmaceuticals, LLC

12.4.1 Company profile

12.4.2 Representative Bile Duct Cancer Drug Product

12.4.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Arrien

Pharmaceuticals, LLC

12.5 Aslan Pharmaceuticals Pte. Ltd.

12.5.1 Company profile

12.5.2 Representative Bile Duct Cancer Drug Product

12.5.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Aslan

Pharmaceuticals Pte. Ltd.

12.6 Bavarian Nordic A/S

12.6.1 Company profile

12.6.2 Representative Bile Duct Cancer Drug Product

12.6.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bavarian

Nordic A/S

12.7 Bayer AG

12.7.1 Company profile

12.7.2 Representative Bile Duct Cancer Drug Product

12.7.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bayer AG

12.8 Blueprint Medicines Corporation

12.8.1 Company profile

12.8.2 Representative Bile Duct Cancer Drug Product

12.8.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Blueprint

Medicines Corporation

12.9 Boehringer Ingelheim GmbH

12.9.1 Company profile

12.9.2 Representative Bile Duct Cancer Drug Product

12.9.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Boehringer

Ingelheim GmbH



## 12.10 Boston Biomedical, Inc.

12.10.1 Company profile

12.10.2 Representative Bile Duct Cancer Drug Product

12.10.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Boston Biomedical, Inc.

## 12.11 Bristol-Myers Squibb Company

12.11.1 Company profile

12.11.2 Representative Bile Duct Cancer Drug Product

12.11.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

## 12.12 Celgene Corporation

12.12.1 Company profile

12.12.2 Representative Bile Duct Cancer Drug Product

12.12.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Celgene Corporation

## 12.13 CellAct Pharma GmbH

12.13.1 Company profile

12.13.2 Representative Bile Duct Cancer Drug Product

12.13.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of CellAct Pharma GmbH

## 12.14 Cellceutix Corporation

12.14.1 Company profile

12.14.2 Representative Bile Duct Cancer Drug Product

12.14.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Cellceutix Corporation

## 12.15 Cellular Biomedicine Group, Inc.

12.15.1 Company profile

12.15.2 Representative Bile Duct Cancer Drug Product

12.15.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Cellular Biomedicine Group, Inc.

## 12.16 Concordia Healthcare Corp.

# **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BILE DUCT CANCER DRUG**

13.1 Industry Chain of Bile Duct Cancer Drug

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BILE DUCT CANCER DRUG**

- 14.1 Cost Structure Analysis of Bile Duct Cancer Drug
- 14.2 Raw Materials Cost Analysis of Bile Duct Cancer Drug
- 14.3 Labor Cost Analysis of Bile Duct Cancer Drug
- 14.4 Manufacturing Expenses Analysis of Bile Duct Cancer Drug

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
  - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference

## I would like to order

Product name: Bile Duct Cancer Drug-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/B553F4D9968MEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B553F4D9968MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970